Delivery strategies in treatments of leukemia
Leukemia is a hematological malignancy associated with the uncontrolled proliferation of
mutant progenitors, suppressing the production of normal blood cells. Current treatments …
mutant progenitors, suppressing the production of normal blood cells. Current treatments …
Chronic myeloid leukemia: beyond BCR-ABL1
T Zhou, LJ Medeiros, S Hu - Current hematologic malignancy reports, 2018 - Springer
Purpose of review In this review, we emphasize up-to-date practical cytogenetic and
molecular aspects of chronic myeloid leukemia (CML) and summarize current knowledge on …
molecular aspects of chronic myeloid leukemia (CML) and summarize current knowledge on …
BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features
NR Neuendorff, T Burmeister, B Dörken… - Annals of …, 2016 - Springer
BCR-ABL-positive acute myeloid leukemia (AML) is a rare subtype of AML that is now
included as a provisional entity in the 2016 revised WHO classification of myeloid …
included as a provisional entity in the 2016 revised WHO classification of myeloid …
Epigenetic guardian: a review of the DNA methyltransferase DNMT3A in acute myeloid leukaemia and clonal haematopoiesis
SF Chaudry, TJT Chevassut - BioMed research international, 2017 - Wiley Online Library
Acute myeloid leukaemia (AML) is a haematological malignancy characterized by clonal
stem cell proliferation and aberrant block in differentiation. Dysfunction of epigenetic …
stem cell proliferation and aberrant block in differentiation. Dysfunction of epigenetic …
Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control?
JE Megías-Vericat, O Ballesta-López, E Barragán… - Blood Reviews, 2020 - Elsevier
Dysregulation of tyrosine kinases (TKs) may play a role in leukemogenesis by promoting
survival and proliferation of acute myeloid leukemia (AML) cells. In AML, the main TKs …
survival and proliferation of acute myeloid leukemia (AML) cells. In AML, the main TKs …
Multi-kinase inhibitors, AURKs and cancer
J Cicenas, E Cicenas - Medical Oncology, 2016 - Springer
Inhibitors that impact function of kinases are valuable both for the biological research as well
as therapy of kinase-associated diseases, such as different cancers. There are quite a …
as therapy of kinase-associated diseases, such as different cancers. There are quite a …
[HTML][HTML] Drug repurposing for the treatment of acute myeloid leukemia
V Andresen, BT Gjertsen - Frontiers in Medicine, 2017 - frontiersin.org
Acute myeloid leukemia (AML) is a heterogeneous disease characterized by the
accumulation of immature myeloid progenitor cells in the bone marrow, compromising of …
accumulation of immature myeloid progenitor cells in the bone marrow, compromising of …
[HTML][HTML] Secondary Philadelphia chromosome acquired during therapy of acute leukemia and myelodysplastic syndrome
H Kurt, L Zheng, HM Kantarjian, G Tang… - Modern Pathology, 2018 - Elsevier
The Philadelphia chromosome resulting from t (9; 22)(q34; q11. 2) or its variants is a
defining event in chronic myeloid leukemia. It is also observed in several types of de novo …
defining event in chronic myeloid leukemia. It is also observed in several types of de novo …
Relatively favorable outcome after allogeneic stem cell transplantation for BCR‐ABL1‐positive AML: A survey from the acute leukemia working party of the European …
VL Lazarevic, M Labopin, W Depei… - American journal of …, 2018 - Wiley Online Library
The aim of the study was to assess the role of allogeneic stem cell transplantation (SCT) in
patients diagnosed with BCR‐ABL1‐positive acute myeloid leukemia (AML). Fifty‐seven …
patients diagnosed with BCR‐ABL1‐positive acute myeloid leukemia (AML). Fifty‐seven …
[HTML][HTML] NPM1 mutated, BCR-ABL1 positive myeloid neoplasms: review of the literature
G Catalano, P Niscola, C Banella… - … of Hematology and …, 2020 - ncbi.nlm.nih.gov
Breakpoint cluster region-Abelson (BCR-ABL1) chimeric protein and mutated
Nucleophosmin (NPM1) are often present in hematological cancers, but they rarely coexist …
Nucleophosmin (NPM1) are often present in hematological cancers, but they rarely coexist …